NGL Fine-Chem (NSE:NGLFINE) ROCE %: 19.04% (As of Mar. 2026)


NSE:NGLFINE NGL Fine-Chem Ltd NSE:NGLFINE
78 GF Score
Price ₹2,989.90
GF Value ₹2,836.47
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is NGL Fine-Chem ROCE %?

NGL Fine-Chem NSE:NGLFINE -2.72% 78 ROCE % is 19.04% as of Mar. 2026. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,836.47 (Fairly Valued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NGL Fine-Chem's annualized ROCE % for the quarter that ended in Mar. 2026 was 19.04%.

NGL Fine-Chem  (NSE:NGLFINE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NGL Fine-Chem ROCE % Related Terms

NGL Fine-Chem ROCE % Historical Data

* Premium members only.

The historical data trend for NGL Fine-Chem's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NGL Fine-Chem ROCE % Chart

NGL Fine-Chem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.17 12.98 22.40 10.30 19.11

NGL Fine-Chem Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.59 16.62 16.44 25.31 19.04
NSE:NGLFINE
78GF Score
NGL Fine-Chem Ltd NSE:NGLFINE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NGL Fine-Chem ROCE % Calculation

NGL Fine-Chem's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=678.352/( ( (4333.913 - 1189.7) + (5454.958 - 1500.139) )/ 2 )
=678.352/( (3144.213+3954.819)/ 2 )
=678.352/3549.516
=19.11 %

NGL Fine-Chem's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=752.804/( ( (0 - 0) + (5454.958 - 1500.139) )/ 1 )
=752.804/( ( 0 + 3954.819 )/ 1 )
=752.804/3954.819
=19.04 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 19.04% mean?
NGL Fine-Chem (NSE:NGLFINE) has a ROCE % of 19.04% as of Mar. 2026.
Is NGL Fine-Chem's ROCE % too high?
NGL Fine-Chem's current ROCE % is 19.04%. The Drug Manufacturers industry median ROCE % is 7.00. NGL Fine-Chem's value of 19.04% is 172.2% above this industry median. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's ROCE % compare to LLY and JNJ?
NGL Fine-Chem's ROCE % of 19.04% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. NGL Fine-Chem's value of 19.04% is 172.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current ROCE % of 19.04% is 172.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current ROCE % is 19.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,836.47, compared to a current price of ₹2,989.90 — trading 5.4% above its estimated fair value. The current ROCE % is 19.04% and 172.2% above the Drug Manufacturers industry median of 7.00. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current ROCE % is 19.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?

Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued. The current stock price of ₹2,989.90 is trading 5.4% above its estimated GF Value™ of ₹2,836.47. GuruFocus considers NGL Fine-Chem to be Fairly Valued.

Key valuation signals for NSE:NGLFINE:

  • ROCE %: 19.04%
  • GF Value™: ₹2,836.47 vs. price of ₹2,989.90 (5.4% above fair value)
  • GF Score™: 78/100 with 8 warning signs
  • Industry Position: 172.2% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NGL Fine-Chem Business Description

Other Exchanges 524774:India
Address 301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score

Get the complete analysis for NSE:NGLFINE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,989.90
Price
₹2,836.47
GF Value